Stay updated on SAR422459 in Stargardt's Macular Degeneration Clinical Trial
Sign up to get notified when there's something new on the SAR422459 in Stargardt's Macular Degeneration Clinical Trial page.

Latest updates to the SAR422459 in Stargardt's Macular Degeneration Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded site Revision: v3.4.2 and removed older Revision: v3.4.1 along with a government-funding operating-status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about government funding and operating status was added, with links to cc.nih.gov and opm.gov for updates. The site version was updated to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary toggle and minor wording edits to labels (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data') and updated the revision tag from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 is shown on the page, replacing the previous v3.3.3. There are no apparent changes to core trial details like objectives, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations section updated to include Florida, Iowa, Oregon, and Texas. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.5%

- Check92 days agoChange DetectedThe Publications section wording was updated to clarify that publications are auto-filled from PubMed, and the page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to SAR422459 in Stargardt's Macular Degeneration Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAR422459 in Stargardt's Macular Degeneration Clinical Trial page.